Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 4
1954 5
1956 1
1957 3
1958 1
1959 3
1960 4
1961 3
1962 4
1963 8
1964 3
1965 5
1966 1
1967 4
1968 4
1969 5
1970 1
1971 3
1973 2
1974 2
1975 2
1976 6
1977 1
1978 2
1980 1
1982 1
1983 2
1984 3
1985 4
1986 4
1987 7
1988 7
1989 3
1990 3
1991 6
1993 3
1994 7
1995 4
1996 4
1997 4
1998 8
1999 4
2000 7
2001 11
2002 18
2003 19
2004 20
2005 18
2006 33
2007 36
2008 29
2009 47
2010 50
2011 47
2012 56
2013 69
2014 65
2015 81
2016 85
2017 95
2018 126
2019 116
2020 143
2021 161
2022 180
2023 123
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

1,652 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: li cc. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, O'Hear C, Huang H, Kwan A, Li CC, Piccione EC, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: li cc. J Clin Oncol. 2022 Feb 10;40(5):481-491. doi: 10.1200/JCO.21.00931. Epub 2021 Dec 16. J Clin Oncol. 2022. PMID: 34914545 Free PMC article. Clinical Trial.
New targeted treatments for advanced sarcomas.
Li CC, Chen TW. Li CC, et al. Curr Opin Oncol. 2023 Jul 1;35(4):309-314. doi: 10.1097/CCO.0000000000000955. Epub 2023 May 3. Curr Opin Oncol. 2023. PMID: 37222206 Review.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, Yoon SS, Panizo C, Flinn I, Johnston A, Bosch F, Sehn LH, Wei MC, Yin S, To I, Li CC, Huang H, Kwan A, Penuel E, Budde LE. Bartlett NL, et al. Among authors: li cc. Blood Adv. 2023 Sep 12;7(17):4926-4935. doi: 10.1182/bloodadvances.2022009260. Blood Adv. 2023. PMID: 37067952 Free PMC article.
Asymmetric Total Synthesis of Taxol.
Hu YJ, Gu CC, Wang XF, Min L, Li CC. Hu YJ, et al. Among authors: li cc. J Am Chem Soc. 2021 Oct 27;143(42):17862-17870. doi: 10.1021/jacs.1c09637. Epub 2021 Oct 12. J Am Chem Soc. 2021. PMID: 34641680
1,652 results